{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:33:44Z","timestamp":1760488424063,"version":"build-2065373602"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01513-z","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:33:55Z","timestamp":1754656435000},"page":"3065-3068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Letter to the Editor Regarding: \u201cCardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta\u2011Analysis\u201d"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01472-5","author":"A Shi","year":"2025","unstructured":"Shi A, Shu Y, Haddad JE, et al. Cardiovascular and kidney outcomes after systemic treatment for plaque psoriasis: a systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2025. https:\/\/doi.org\/10.1007\/s13555-025-01472-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1513_CR2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/eb-2018-102911","volume":"21","author":"O Efthimiou","year":"2018","unstructured":"Efthimiou O. Practical guide to the meta-analysis of rare events. Evid Based Ment Health. 2018;21(2):72\u20136.","journal-title":"Evid Based Ment Health"},{"issue":"6","key":"1513_CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jrsm.1662","volume":"14","author":"K Jansen","year":"2023","unstructured":"Jansen K, Holling H. Rare events meta-analysis using the Bayesian beta-binomial model. Res Synth Methods. 2023;14(6):853\u201373.","journal-title":"Res Synth Methods"},{"key":"1513_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10543406.2025.2512205","volume":"9","author":"O Alqasem","year":"2025","unstructured":"Alqasem O, Demirhan H, Dolgun A. Bayesian meta-analysis for rare outcomes. J Biopharm Stat. 2025;9:1\u201323.","journal-title":"J Biopharm Stat"},{"issue":"13","key":"1513_CR5","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zang J, Liu C, Yan Z, Shi D. Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis. Front Immunol. 2022;13(13): 835671.","journal-title":"Front Immunol"},{"issue":"4","key":"1513_CR6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jdv.16018","volume":"34","author":"W Rungapiromnan","year":"2020","unstructured":"Rungapiromnan W, Mason KJ, Lunt M, et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol. 2020;34(4):769\u201378.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1513_CR7","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","volume":"155","author":"MP Lee","year":"2019","unstructured":"Lee MP, Desai RJ, Jin Y, et al. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol. 2019;155(6):700\u20137.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1513_CR8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2025.03.016","volume":"93","author":"J Banefelt","year":"2025","unstructured":"Banefelt J, Skr\u00f6der H, Azzabi A, et al. Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: results from an observational postauthorization safety study based on Swedish national registers. J Am Acad Dermatol. 2025;93(1):104\u201314.","journal-title":"J Am Acad Dermatol"},{"key":"1513_CR9","doi-asserted-by":"publisher","unstructured":"Gelfand JM, Shin DB, Alavi A, Torigian DA, Werner T, Papadopoulos M, Takeshita J, Noe MH, Dey AK, Playford MP, Mehta NN. A Phase IV, Randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol. 2020;140(1):85\u201393.e2. https:\/\/doi.org\/10.1016\/j.jid.2019.07.679","DOI":"10.1016\/j.jid.2019.07.679"},{"key":"1513_CR10","doi-asserted-by":"publisher","unstructured":"Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther. 2022;9(3):935\u2013955. https:\/\/doi.org\/10.1007\/s40744-022-00434-z","DOI":"10.1007\/s40744-022-00434-z"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01513-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01513-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01513-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:52:26Z","timestamp":1760457146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01513-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01513-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"References 9 and 10 updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA and UCB. Luis Puig has received consultancy\/speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius-Kabi, Horizon (DSMB), J&J Innovative Medicine, Leo-Pharma, Lilly, Novartis, Pfizer, Samsung Bioepis, STADA, Sun-Pharma, Takeda, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}